Medical Digest & Congress Report

Professor Andrea Botticelli presented the Rome trial results at ESMO 24 Presidential Session. Patients with advanced cancers receiving tumor-agnostic treatments based on the recommendations of a molecular tumor board had significantly better response rates and lived longer without the disease progressing than those receiving the standard of care in the ROME trial.

Video: https://medicaldigest.org/scientific-contents/interview:rome-trial-histology-target-road-personalize-targeted-therapy-and-immunotherapy

Professor Aristotelis Bamias shares his thoughts on genitourinary tumours highlights of the ESMO 2024 Congress.

Video: https://medicaldigest.org/scientific-contents/interview:genitourinary-tumours-non-prostate-highlights-esmo-2024-congress

Professor Jianjun Zhang shares his thoughts on lung cancer screening and prevention.

Video: https://medicaldigest.org/scientific-contents/interview:lung-cancer-interception-new-approaches-lung-cancer-screening-and-prevention

Professor Domenica Lorusso presented the overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer.

Video: https://medicaldigest.org/scientific-contents/interview:pembrolizumab-plus-chemoradiotherapy-high-risk-locally-advanced-cervical-cancer-overall-survival-results-randomized-double-blind-phase-3-engot-cx11gog-3047keynote-a18-study

Professor Josep Llovet discusses the results of LEAP-012 Study which he presented at ESMO 2024.

Video: https://medicaldigest.org/scientific-contents/interview:leap-012-study-transarterial-chemoembolization-or-without-lenvatinib-pembrolizumab-intermediate-stage-hepatocellular-carcinoma

Professor Silke Gillessen discussing results from STAMPEDE trial assessing the addition of metformin to ADT for patients with mHSPC.

Video: https://medicaldigest.org/scientific-contents/interview:adding-metformin-adt-patients-mhspc-overall-survival-results-multi-arm-multi-stage-randomized-platform-trial-stampede

Professor Silke Gillessen presented new results from the PEACE-3 trial at the 2024 ESMO conference. This study indicates that combining Enzalutamide with Radium223 significantly improves progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases over Enzalutamide alone.

Video: https://medicaldigest.org/scientific-contents/interview:peace-3-trial-shows-combination-therapy-improves-survival-prostate-cancer-report-esmo2024

Professor Peter Schmid presented the overall survival results from the phase 3 KEYNOTE-522 study at ESMO 2024 Congress. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC.

Video: https://medicaldigest.org/scientific-contents/interview:neoadjuvant-pembrolizumab-or-placebo-plus-chemotherapy-followed-adjuvant-pembrolizumab-or-placebo-high-risk-early-stage-tnbc-overall-survival-results-phase-3-keynote-522-study

Professor Dominik P. Modest shares his thoughts on POD1UM-303/InterAACT 2 study, which are potentially practice-changing findings in squamous cell carcinoma of the anal canal.

Video: https://medicaldigest.org/scientific-contents/interview:pod1um-303interaact-2-potentially-practice-changing-findings-scac-report-esmo2024

Professor Tony S.K. Mok shares his thoughts on setting a new benchmark for ALK+ aNSCLC targeted therapy.

Video: https://medicaldigest.org/scientific-contents/interview:setting-new-benchmark-alk-ansclc-targeted-therapy-report-esmo2024